ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2026, Vol. 35 ›› Issue (1): 8-14.DOI: 10.3969/j.issn.1006⁃298X.2026.01.002

• 论著 • 上一篇    下一篇

糖皮质激素辅助治疗慢性肾脏病继发耶氏肺孢子菌肺炎的临床研究

  

  • 出版日期:2026-02-27 发布日期:2026-02-27

Adjunctive glucocorticoids for pneumocystis jirovecii pneumonia in patients with immunodeficiency kidney disease

  • Online:2026-02-27 Published:2026-02-27

摘要: 目的:回顾性分析肾脏病继发耶氏肺孢子菌肺炎 (PJP) 患者的临床特点与预后,重点评估糖皮质激素辅助治疗 PJP 的效果。方法:纳入 2009 年 8 月至 2025 年 6 月国家肾脏疾病临床医学研究中心收治的 PJP 患者,根据预后分为好转组和死亡组,分析其临床特征及预后;根据甲泼尼龙 (MP) 最大治疗剂量分为标准剂量激素组 (MP=80 mg/d) 272 例和小剂量激素组 (MP≤40 mg/d) 84 例,分析糖皮质激素辅助治疗的作用。结果:共有 356 例肾脏病继发免疫缺陷患者临床诊断为 PJP。原发肾脏病包括同种异体肾移植术后 131 例 (36.8%), 狼疮性肾炎 48 例 (13.5%), 足细胞病 43 例 (12.1%), 膜性肾病 40 例 (11.2%) 等。治疗后 257 例 (72.2%) 好转出院,99 例 (27.8%) 死亡。多因素 Logistic 回归分析发现,高龄、入院第 3 天高热、血小板计数低、氧合指数低、CD4+T 淋巴细胞计数低提示预后差。受试者工作特征曲线显示,联合预测模型的曲线下面积为 0.925。与小剂量激素组相比,标准剂量激素组患者死亡率明显下降,机械通气脱机率更高,C 反应蛋白水平和体温下降更快。两组患者继发感染及消化道出血等不良事件的发生率差异无统计学意义。结论:辅助使用标准剂量糖皮质激素可显著降低肾脏病继发免疫缺陷 PJP 患者的死亡率,提高机械通气脱机率,更快降低炎症指标,且没有增加感染及消化道出血等不良事件。

关键词: 肾脏病, 耶氏肺孢子菌肺炎, 糖皮质激素, 临床特征, 预后

Abstract: Objective:A retrospective analysis was conducted on the clinical characteristics and prognosis of patients with Pneumocystis jirovecii Pneumonia (PJP) secondary to kidney disease with immunodeficiency,with a focus on evaluating the efficacy of adjunctive glucocorticoid therapy in these patients. Methods:Patients with PJP admitted to the National Clinical Research Center for Kidney Diseases from August 2009 to June 2025 were included and divided into improvement and mortality groups based on prognosis. Their clinical characteristics and prognosis were analyzed. Patients were divided into a standard-dose glucocorticoid group (MP=80 mg/d) 272 cases and a low-dose glucocorticoid group (MP≤40 mg/d) 84 cases based on different methylprednisolone treatment doses,to analyze the role of adjunctive glucocorticoid therapy. Results:A total of 356 patients with kidney disease and secondary immunodeficiency were clinically diagnosed with PJP. The primary kidney diseases included 131 cases(36.8%)of post⁃allogeneic renal transplantation,48 cases(13.5%)of lupus nephritis,43 cases(12.1%)of podocytopathy,and 40 cases(11.2%)of membranous nephropathy among others. After treatment,257 cases(72.2%)improved and were discharged,while 99 cases(27.8%)died. Multivariate logistic regression analysis revealed that advanced age,high fever on the third day of admission,low platelet count,low oxygenation index,and low CD4+T cell count indicated a poor prognosis. The ROC curve demonstrated that the combined prediction model has a high AUC(0.925). Compared with the low⁃dose glucocorticoid group,the standard⁃dose group showed significantly lower mortality,higher mechanical ventilation weaning rate,and faster reduction in CRP levels and body temperature. There was no significant difference in the incidence of adverse events such as secondary infections and gastrointestinal bleeding between the two groups (P>0.05). Conclusion: Adjuvant use of standard-dose glucocorticoids can significantly reduce mortality in Pneumocystis jirovecii Pneumonia patients with immunodeficiency kidney disease,improve mechanical ventilation weaning rates,accelerate the reduction of inflammatory markers,and does not increase adverse events such as infections or gastrointestinal bleeding.

Key words: kidney disease, pneumocystis jirovecii pneumonia, glucocorticoid, clinical characteristics, prognosis